THE SHORT ANSWER
Does CVS Caremark Cover Foundayo?
CVS Caremark No Longer Blocks Foundayo as a New Drug
It depends on your plan. Foundayo (orforglipron) was FDA approved on April 1, 2026. CVS Caremark ended its new-to-market block on Foundayo on June 1, 2026, where plans have approved it for coverage.[1] Employers and plans can customize their formulary, so check your own plan's formulary.
CVS Caremark's standard commercial formularies list Wegovy (semaglutide) and, since October 1, 2026, Zepbound as preferred GLP-1s for weight loss. If your plan uses CVS Caremark and doesn't cover Foundayo, here are your options:
- Self-pay via LillyDirect — $149–$299/month depending on dose
- Request a formulary exception — If your plan doesn't cover Foundayo
- Check with your employer — Self-funded plans can add coverage independently
- Use the Lilly Savings Card — If you have commercial coverage, may pay as low as $25/month
Important: CVS Caremark is a pharmacy benefit manager (PBM), not an insurance company. Your employer or insurer contracts with CVS Caremark to manage prescription benefits. Some employers may negotiate custom formularies—always verify with your specific plan.
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get starteddenied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
"I found Honest Care online and was very impressed with the letter... the appeal worked!"
"My Appeal was approved the next day. Thank you Honest Care!"
WHY THIS MATTERS FOR YOUR COVERAGE
Understanding CVS Caremark as a PBM
CVS Caremark is a pharmacy benefit manager (PBM)—a middleman between your insurance company and pharmacies. They're one of the "Big 3" PBMs (alongside Express Scripts and OptumRx) that together process about 80% of all U.S. prescription claims.[2]
| Role | What They Do | Examples |
|---|---|---|
| Insurance Company | Sets overall benefits, pays claims, decides what's covered | Blue Cross, Aetna, UnitedHealthcare, Cigna |
| Employer (Self-Funded) | May customize drug benefits beyond standard formulary | Large corporations, government entities |
| PBM (CVS Caremark) | Manages formulary, processes Rx claims, negotiates drug prices | CVS Caremark, Express Scripts, OptumRx |
Why Does This Matter?
CVS Caremark manages pharmacy benefits for Aetna and many employers. When CVS Caremark doesn't add a drug to its formulary, it affects tens of millions of Americans—but not everyone uniformly:
- Employers can opt out — Self-funded employers can negotiate to add Foundayo to their specific formulary
- Your insurer may override — Some insurers contract with CVS Caremark but require different formulary rules
- Exceptions are possible — Even non-covered drugs can be covered via formulary exception requests
How to Check Your Specific Coverage
Your ID card tells you who to call. Look for "Rx Bin" or "Pharmacy" on your card—if it shows CVS Caremark, your prescription benefits are managed by them. But your employer or insurer may have negotiated different terms.
Call both: (1) your HR department and (2) the number on your card.
UNDERSTANDING THE CONTEXT
Why Your CVS Caremark Plan May Not Cover Foundayo
Until June 1, 2026, CVS Caremark blocked Foundayo as a new-to-market drug. CVS Caremark ended its new-to-market block on Foundayo on June 1, 2026.[1] If your plan still doesn't cover it, two things are usually behind it:
1. Foundayo Is Still New
Foundayo (orforglipron) was just FDA approved on April 1, 2026.[3] As Eli Lilly's first GLP-1 pill for weight management, it is still new, and each plan decides whether to approve it for coverage.
2. CVS Caremark’s Recent GLP-1 Formulary Changes
On July 1, 2025, CVS Caremark made Zepbound (tirzepatide)—a different Eli Lilly obesity drug—nonpreferred or excluded on its most common commercial template formularies (including Standard, Advanced Control, and Value; plan sponsors could customize) and made Wegovy its preferred GLP-1 for weight loss after a rebate deal with Novo Nordisk.[4] Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize), alongside Wegovy.[1]
Important Distinction
Foundayo was NOT "removed" from CVS formularies. The July 2025 formulary change was CVS dropping Zepbound (a different Lilly drug) on its most common commercial formularies.
Current GLP-1 Formulary Status
Here's the current status of GLP-1 medications on CVS Caremark's standard commercial formularies as of October 2026 (your plan may differ):
| Medication | Indication | Standard Formulary | Notes |
|---|---|---|---|
| Foundayo (orforglipron) | Weight loss | Plan-dependent | New-to-market block ended June 1, 2026 |
| Wegovy (semaglutide) | Weight loss | Preferred | Preferred since July 1, 2025 |
| Zepbound (tirzepatide) | Weight loss | Preferred | Preferred again on the commercial template formularies since October 1, 2026 (nonpreferred or excluded on the most common ones July 1, 2025 – September 30, 2026) |
| Mounjaro (tirzepatide) | Type 2 diabetes | Covered | Diabetes indication only |
| Ozempic (semaglutide) | Type 2 diabetes | Covered | Diabetes indication only |
Key insight: CVS Caremark ended its new-to-market block on Foundayo on June 1, 2026, and Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize).[1] Employers and plans can still customize their formulary, so some plans may exclude Foundayo—check your own plan's formulary.
YOUR OPTIONS
What If Your Plan Uses CVS Caremark?
If your CVS Caremark plan doesn't cover Foundayo, you still have options:
Step 1: Verify Your Specific Plan
Self-funded employers can customize their drug coverage independently of CVS Caremark's standard formularies. Contact your HR department to ask:
Questions for HR
- Is our plan self-funded or fully insured?
- Can our plan add coverage for newly-approved medications?
- Has the company considered adding GLP-1 coverage for weight management?
- What's the process to request a formulary exception?
Step 2: Call CVS Caremark
Call Script for CVS Caremark
"Hi, I'm calling to check coverage for a prescription medication. My member ID is [NUMBER]. I need to know:
- Is Foundayo (orforglipron) covered on my specific plan's formulary for weight management?
- If not on formulary, does my employer's plan allow formulary exceptions?
- What documentation is needed for a formulary exception request?
- Can I get this coverage determination in writing?"
Step 3: Consider Your Alternatives
- Self-pay via LillyDirect — At $149–$299/month, this is often more affordable than expected
- Check step-therapy rules — Some plans may require trying another drug first; check your plan’s criteria
- Compare other insurers — During open enrollment, evaluate plans using different PBMs
IF YOUR PLAN DOESN'T COVER FOUNDAYO
How to Request a Formulary Exception
If your plan doesn't cover Foundayo, you can request a formulary exception:
Document Any Required Drug Trials
Some plans may require trying another drug first; check your plan’s criteria. If your plan requires another drug first, work with your doctor to document that trial and its results or side effects.
Gather Medical Necessity Documentation
Your doctor prepares a Letter of Medical Necessity explaining why Foundayo is specifically needed for your case.
Submit Exception Request
Your doctor submits the request through CVS Caremark's exception process, including BMI (Body Mass Index) records and documentation of any other drugs your plan requires you to try first.
Appeal If Denied
If denied, you typically have 180 days to appeal (commercial plans; for a Medicare Part D plan, appeal within 65 days from the date on the denial notice). Many appeals succeed—don't give up after the first denial.
Exception Requirements
- BMI ≥30, or ≥27 with a comorbidity (diabetes, hypertension, sleep apnea)
- Prior drug trials, if your plan requires them — Some plans may require trying another drug first; check your plan’s criteria
- Letter of Medical Necessity from your prescribing physician
For complete guidance, see our Formulary exception guide →
GETTING FOUNDAYO WITHOUT CVS CAREMARK COVERAGE
Self-Pay and Savings Options
For most CVS Caremark patients, self-pay via LillyDirect is the primary path to Foundayo. Here's what you'll pay:
| Dose | LillyDirect Price | Notes |
|---|---|---|
| 0.8mg (starting) | $149/month | Month 1 |
| 2.5mg | $149/month | Month 2 (temporary price through December 31, 2026) |
| 5.5mg | $199/month | Months 3-4 (temporary price through December 31, 2026) |
| 9mg | $299/month | Month 5+ |
| 14.5mg, 17.2mg | $299/month | Maintenance doses, if refilled within 45 days |
| 14.5mg, 17.2mg (refill more than 45 days late) | $349/month | Regular price for the top doses |
Lilly Savings Card
If you have commercial insurance (even without Foundayo coverage), the Lilly Savings Card can help:
| Situation | Your Cost | Limits |
|---|---|---|
| WITH commercial insurance coverage | As low as $25/month | Max $100 savings per fill, $1,000/year |
| WITHOUT coverage | $149–$299/month | Brings cost to LillyDirect levels |
Savings Card Exclusions
The Lilly Savings Card is NOT available to:
- Medicare enrollees (Part D, Medicare Advantage)
- Medicaid enrollees
- Other government healthcare programs (VA, TRICARE)
Card valid through 12/31/2026. Maximum savings: $100 per fill, $1,000/year cap.
For more cost options, see our LillyDirect guide → or Savings card guide →
WHAT'S LIKELY
CVS Caremark Coverage Outlook for 2026
CVS Caremark ended its new-to-market block on Foundayo on June 1, 2026. Here's where things stand:
- Plans decide whether to cover Foundayo; some may still exclude it[1]
- Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize)
- Wegovy remains preferred (Novo Nordisk)
- Over 95% of CVS GLP-1 utilization is now on preferred products[5]
What Could Change Coverage
| Factor | Status | Potential Impact |
|---|---|---|
| Class Action Lawsuit | Pending (re: Zepbound removal) | Settlement could affect Lilly drug coverage broadly[6] |
| FTC PBM Lawsuit | Active against CVS, Express Scripts, OptumRx | Currently focused on insulin; could expand to GLP-1s |
| Employer Demand | Growing | Large employers may negotiate custom formularies |
| Competitive Pressure | Oral GLP-1s gaining traction | If Oral Wegovy gains share, CVS may reconsider Foundayo |
Best Path Forward
If your plan doesn't cover Foundayo, self-pay via LillyDirect ($149–$299/month) is the most reliable path for CVS Caremark patients who want Foundayo.
CVS CAREMARK FOUNDAYO COVERAGE
Frequently Asked Questions
It depends on your plan. Foundayo was FDA approved on April 1, 2026. CVS Caremark ended its new-to-market block on Foundayo on June 1, 2026, where plans have approved it for coverage. Some plans may still exclude it, so check your plan's formulary. If your plan doesn't cover it, self-pay via LillyDirect ($149–$299/month) is the main alternative.
CVS Caremark ended its new-to-market block on Foundayo on June 1, 2026, so Foundayo is no longer blocked as a new drug. Whether your plan covers it depends on your plan: employers and plans can customize their formulary. For context, From July 1, 2025 to September 30, 2026, Zepbound was nonpreferred or excluded on CVS Caremark’s most common commercial formularies, with Wegovy preferred; Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize).
Possibly. If your employer has a self-funded plan, they can customize drug coverage independently of CVS Caremark's standard formularies. Ask your HR department if adding Foundayo coverage is possible. Large employers sometimes negotiate custom formularies for medications in high demand.
Through LillyDirect, prices range from $149/month (0.8mg starting dose) to $299/month (maintenance doses). If a 14.5mg or 17.2mg refill is more than 45 days late, the price is $349/month. If you have commercial insurance that covers Foundayo, the Lilly Savings Card may bring your cost as low as $25/month.
CVS Caremark's standard commercial formularies prefer Wegovy (semaglutide), and Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize) (it was nonpreferred or excluded on the most common ones July 1, 2025 – September 30, 2026). CVS Caremark ended its new-to-market block on Foundayo on June 1, 2026, so Foundayo coverage depends on your plan.
YOUR PATH FORWARD
What's Next
Foundayo Coverage: Other Major Insurers
Coverage varies by insurer. See insurer-specific guides:
- Aetna — Coverage varies; uses CVS Caremark as PBM
- Blue Cross Blue Shield — Coverage varies by plan
- Cigna — Coverage developing; check your specific plan
- UnitedHealthcare — Coverage varies by plan
Other GLP-1 Medications at CVS Caremark
CVS Caremark's coverage varies by medication. Compare your options:
References
- CVS Health. (2026). "CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options." cvshealth.com
- Drug Channels. (2026). "The Top Pharmacy Benefit Managers of 2025." drugchannels.net
- Eli Lilly. (2026). "FDA Approves Lilly's Foundayo (orforglipron), the Only GLP-1 Pill for Weight Loss That Can Be Taken Any Time of Day Without Food or Water Restrictions." prnewswire.com
- Mass.gov. (2025). "CVS Caremark decides to remove Zepbound from CVS Caremark formulary." mass.gov
- CVS Caremark Business. (2025). "Enabling wider access to effective weight management treatment." business.caremark.com
- Fierce Healthcare. (2025). "CVS Caremark hit with class-action lawsuit over decision to drop Zepbound from formulary." fiercehealthcare.com
Last updated October 6, 2026 · Key facts verified October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.